Valneva (NASDAQ:VALN) Shares Gap Down to $8.88

Valneva SE (NASDAQ:VALN - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $8.88, but opened at $8.69. Valneva shares last traded at $8.69, with a volume of 1,111 shares.

Wall Street Analyst Weigh In

VALN has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $26.00 price target on shares of Valneva in a research note on Wednesday, May 8th. Guggenheim decreased their price target on shares of Valneva from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Friday, March 22nd.

Valneva Stock Down 0.5 %

The firm has a market cap of $615.62 million, a PE ratio of -21.56 and a beta of 2.22. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64. The firm's 50-day moving average price is $7.88 and its two-hundred day moving average price is $9.09.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.70). The company had revenue of $45.12 million for the quarter, compared to analysts' expectations of $45.06 million. Valneva had a negative return on equity of 14.56% and a negative net margin of 15.88%. As a group, equities research analysts expect that Valneva SE will post -0.28 EPS for the current fiscal year.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. boosted its holdings in Valneva SE (NASDAQ:VALN - Free Report) by 2.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 354,361 shares of the company's stock after purchasing an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.39% of the company's stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.